Our 2026 Annual General Meeting is coming up on Thursday, 19 November 2026 at 10:00am (AWST), at the QV1 Conference Centre in Perth. The Notice of Meeting, Explanatory Statement and Proxy Form are all available on our website, and we've set out below what's on the agenda.

Alongside receiving our annual financial report for the year to 30 June 2026, shareholders are being asked to vote on eight resolutions. These include the usual annual items: a non-binding vote on our Remuneration Report, the election of Michael Sistenich and David Fuller (both appointed to the Board in April 2026) and the re-election of Travis Baroni, who retires by rotation.

There are also several resolutions dealing with our capital management and incentive arrangements. We're seeking shareholder approval for an additional 10% placement capacity under ASX Listing Rule 7.1A, a fresh mandate to issue up to 35,000,000 securities under our Incentive Awards Plan, and the issue of up to 6,850,749 loan shares to director Andrew Harrison in satisfaction of his long-term incentive entitlement for FY26, funded by a limited-recourse loan on the terms set out in the Explanatory Statement. We're also asking shareholders to approve raising the issue cap in our Constitution from 5% to 15%, to give us more flexibility under our employee incentive scheme.

Full details on each resolution, including the dilution tables, valuation assumptions and voting exclusions that apply, are in the Notice and Explanatory Statement, which we'd encourage you to read in full before voting.

Shareholders can vote in person, by proxy or by appointing a representative, and proxy forms need to be received by 10:00am (AWST) on Tuesday, 17 November 2026.

If anything in the Notice raises a question for you, we'd welcome you asking it through the question box on this page.

We're letting you know that preliminary results from our MRI Liver Fibrosis Device EPoC clinical trial are expected on Wednesday 28 October 2026, and we'd like to walk you through them directly.

Andrew Harrison, our MD and CEO, and Dr Wenjie Pang, our Chief Scientific Officer, will host a webinar that day at 10:00am AWST to talk through the trial, the methods used, and the key outcomes. A recording will also be available on our Investor Centre homepage within 24 hours for anyone who can't join live.

This trial matters because it's a bigger, more rigorous step than our initial proof-of-concept, which showed strong predictive capability for identifying liver fibrosis back in December 2022. Liver fibrosis is linked to common conditions like MASLD and MASH, which affect an estimated one-quarter of the world's population. The current gold standard for detecting it, a liver biopsy, is invasive and carries real risks and costs. A reliable, non-invasive MRI-based alternative would address a genuine gap in how liver disease is managed, and this EPoC trial is a key inflection point on the path towards certifying such a device.

We want to be clear these are preliminary results from an extended-proof-of-concept trial, a step on the regulatory and development roadmap rather than a finished, certified product.

If you have questions about this announcement, you're welcome to send them through the question box on this page.

We've set the date for this year's Annual General Meeting: Thursday, 19 November 2026.

If you're interested in nominating someone for the Board, or putting your own hand up, nominations close 5:00pm (AWST) on Wednesday, 7 October 2026. Nominations need to be in writing, with consent to act attached, and received at our registered office at Level 1, 141-143 Burswood Road, Burswood, WA 6100 by that time.

The full Notice of Meeting and Explanatory Memorandum, with all the detail you'll need ahead of the AGM, will follow in due course. We'll lodge it with the ASX and make it available on our investor website as well.

This announcement is just the formal heads-up required under our Constitution and the ASX Listing Rules. There's nothing else to act on right now unless you're considering a Board nomination.

If you have questions about the AGM or the nomination process, please use the question box on this page.

A change of substantial holder notice has been lodged with Resonance Health, relating to the combined holdings of The Design Counsel Pty Ltd and Southam Investments 2003 Pty Ltd, associated entities linked to Karen Panton and Simon Panton.

The notice shows their combined voting power has moved from 18.02% to 16.8%, even though the actual number of shares held has increased, from 72,546,350 shares to 80,137,174 shares. This kind of shift happens when a substantial holder's shareholding grows more slowly than the total number of shares on issue, so their percentage stake can fall even as their share count rises.

The detailed transaction history shows a series of on-market and off-market purchases stretching from 2019 through to July 2026, with the most recent being an off-market acquisition of 1,640,824 shares for $73,837 on 13 July 2026.

Both entities remain registered holders of their respective parcels, and there is no change reported in their association with each other.

This is a standard regulatory disclosure required whenever a substantial holder's interest changes, and it does not reflect any operational or financial announcement from Resonance Health itself. If you would like to understand what this means for the register or for the company more broadly, we welcome your questions through the hub.

We've signed a Strategic Alliance & Master Services Agreement with Image Analysis Group (IAG), a London-headquartered global imaging clinical research organisation that has supported more than 700 clinical trials since 2007 on its DYNAMIKA™ platform.

Under the agreement, our MRI analysis endpoints, FerriScan®, FerriSmart®, HepaFatScan®, HepaFatSmart®, LiverSmart® and CardiacT2*, become orderable within IAG's global imaging business, still analysed and overseen by our ISO 13485-certified laboratory. In return, we gain access to IAG's imaging infrastructure and global reader network for our own multi-modality studies, and we become IAG's Australian delivery partner for clinical trials, covering feasibility, ethics, local sponsorship and our TrialsWest sites, with a pathway to activities that may qualify for Australia's R&D Tax Incentive.

The alliance targets growth areas including obesity and metabolic disease, iron overload disorders, MASH/MASLD, hepatology and oncology, and it complements our existing R&D pipeline, including our MRI Liver Fibrosis device.

It's worth being clear-eyed about the shape of this deal: it's non-exclusive, runs an initial 24 months with renewal options, carries no minimum volume or revenue commitments, and either party can terminate on 90 days' notice. Revenue will depend entirely on the work orders actually executed under it, and the financial impact cannot be reliably quantified at this stage. The first two work orders will be pilot studies to test the workflow before the parties commit further.

We see this as a capital-light way to extend our regulatory-cleared technologies into a much larger international sponsor network, building on the revenue growth we've delivered from $4M in FY23 to $15.8M in FY26.

If you have questions about this announcement, we'd welcome you asking them through the question box on this page.

Resonance Health has lodged its Corporate Governance Statement for the year ended 30 June 2026, setting out how our board and committees operate and where we've kept pace with the ASX Corporate Governance Council's recommendations.

The headline for shareholders: for most of the year our board wasn't made up mostly of independent directors. Following Martin Blake's retirement as Chair in November 2025, we took the time between then and April 2026 to properly identify the right people for two board vacancies, rather than rushing appointments. Aaron Brinkworth stepped in as independent Chair, and David Fuller and Michael Sistenich joined as independent non-executive directors on 28 April 2026, restoring the board's independent majority. Both new directors will stand for election at the 2026 AGM.

Elsewhere, we've followed the recommendations in full: our audit and risk committee, remuneration committee, and continuous disclosure practices are all in place and operating as expected, and our CEO and CFO continue to provide the standard sign-offs on our financial statements. We don't run a separate internal audit function given our size, relying instead on our ISO13485 quality management system, and we've flagged that a broader risk review is ongoing into FY27. We also don't yet have formal measurable gender diversity targets, though our diversity policy and workforce mix are disclosed.

None of this changes our strategy or operations, it's a report on how the company is governed and who's accountable for what.

The full statement, including committee membership, meeting attendance and remuneration detail, is available on our investor hub, and if anything here raises a question for you, we'd like to hear it.

FY26 was the year our numbers turned. Revenue grew 42% to $15.8M, and we returned to full-year profitability with net profit after tax of $1.5M, compared to a $1.7M loss the year before. Normalised EBITDA rose 83% to $2.6M, and we hit the upgraded guidance we gave the market back in May.

Just as importantly, the cash followed the earnings. We generated positive operating cashflow in every quarter, free cashflow of $2.8M (up 148% on FY25), and finished the year with net cash of $2.3M, a big turnaround from the $0.1M net cash position a year earlier.

All three parts of the business contributed. Resonance Clinical grew 81% and is now our largest segment, TrialsWest's Osborne Park clinic is consistently profitable while Mandurah is tracking ahead of expectations toward breakeven, and our SaMD pipeline now sits above $12.0M in forward orders and tenders. Our liver fibrosis device trial has finished enrolling and data analysis is underway, with results expected in the coming months.

For FY27, we're guiding to revenue of $17M to $22M and Normalised EBITDA of $2.6M to $3.6M. This guidance is based on deliberately modest assumptions, including no new clinic sites, no acquisitions, and no contribution from the liver fibrosis project. Our medium-term goal remains scaling toward $30M in revenue at around a 25% underlying EBITDA margin.

One administrative note: ASX has confirmed we no longer need to lodge quarterly Appendix 4C cashflow reports, given our consistent positive cashflow. We'll keep you informed through our half-year and annual reports, the AGM, investor presentations and ongoing announcements as usual.

If you have questions about any of this, we'd genuinely like to hear them.

FY26 was the year our turnaround showed up in the numbers. Revenue reached $15.8M, up 42% on FY25, and we returned to full-year profit with net profit after tax of $1.5M, a $3.2M swing from last year's loss. Normalised EBITDA rose 83% to $2.6M, lifting our margin from 13% to 16%.

Just as important is the cash behind those numbers. We generated positive operating cashflow in every quarter, with free cashflow of $2.8M, up 148% on FY25. Cash at bank sits at $4.8M and we finished the year with net cash of $2.3M, up from $0.1M a year earlier. ASX has also confirmed we no longer need to lodge quarterly cashflow reports, reflecting that sustained performance.

Each of our three businesses, imaging analysis, clinical trial management and investigator sites, contributed positive profit this year, and all three are backed by contracted work heading into FY27, including $13.8M of trial invoicing still to come and a SaMD pipeline exceeding $12M.

Looking ahead, we've given FY27 guidance of $17M to $22M revenue and $2.6M to $3.6M normalised EBITDA. That guidance is built on existing contracts and pipeline conversion, and deliberately excludes upside from the liver fibrosis device, acquisitions or new sites, so there's more to come if those land. As with all forward-looking guidance, actual results may differ from what we expect.

If you have questions about this result, we'd welcome you raising them through the investor hub.

FY26 was a strong year for Resonance Health, and we wanted you to hear it directly from us.

Group revenue rose 42% to $15,751,909, and we returned to profit with a net profit after tax of $1,513,109, a turnaround of more than $3.3 million on last year's loss. Normalised EBITDA came in at $2,550,000, ahead of the $2.0 million we originally guided the market to expect, guidance we upgraded during the year and then beat.

Just as important to us is the quality behind those numbers. We collected a record $14,280,910 in cash receipts, generated positive operating cash flow in every quarter, and finished the year with $4,849,447 in the bank against $2,533,334 of bank debt. This growth was funded from our own operations, not from raising capital.

All three parts of our business, our imaging software, our clinical research organisation and our TrialsWest site network, grew and reinforced each other this year. Our major MASH clinical trial finished patient recruitment, which is a real achievement, but it also means replacing that revenue is now our key near-term priority as we head into FY27. Our $2,533,334 NAB facility matures in March 2027, and the Board is actively working on its renewal well ahead of that date. Our liver fibrosis device remains under development, funded from our own cash flow, with no revenue from it assumed in our near-term plans.

We also strengthened the Board this year, appointing Dr David Fuller and Michael Sistenich, whose drug development and healthcare investment experience will support the decisions ahead of us.

The full Annual Report, including the detailed financial statements, sits alongside this summary. If anything here raises a question for you, we'd genuinely like to hear it through the question box on this page.

We plan to release our FY26 full year results, covering the 12 months to 30 June 2026, on the ASX on or before 28 August 2026.

To walk you through them, Andrew Harrison and our CFO will host a live webinar for investors and analysts at 10.00 a.m. AWST (12.00 p.m. AEST) on Friday, 28 August 2026. It's interactive, so you can put questions to us directly, either ahead of time or live during the session.

You can register for the webinar through our InvestorHub. If the timing doesn't suit, a recording will be available on the InvestorHub afterwards, so you won't miss it.

This is a straightforward heads-up rather than the results themselves. The numbers and detail behind them will come with the results announcement on or before 28 August, and we'll be talking through those on the day.

If you'd like to register or have questions about the webinar, you're welcome to ask us through the question box on this page.

Resonance Health Limited (ASX: RHT) has released an 'MRI Liver Fibrosis Device Progress & FY26 Portfolio Update' investor presentation. Investors are invited to join a live webinar on June 9th, 2026, to learn more about the company's progress. The webinar will be hosted by the Managing Director & CEO, Andrew Harrison, and Chief Scientific Officer, Dr Wenjie Pang.

The company's dedication to scientific rigour and quality has led to regulatory clearances for a range of Software-as-Medical-Devices (SaMDs) in the USA, Europe, UK, and Australia. Resonance Health's products have gained endorsement from leading physicians worldwide.

The development pipeline includes the MRI Liver Fibrosis Project, aimed at accurately assessing liver fibrosis progression using non-invasive MRI analysis. This presents a significant opportunity in the $40B+ liver diagnostics market.

Resonance Health's profitable platform, combined with the upcoming Liver Fibrosis device launch, positions the company for significant growth. The company's global reach, regulatory moat, and alignment with the GLP-1 trial boom highlight the potential for further expansion.

For further details and to participate in the webinar, please visit our website or contact Andrew Harrison, Managing Director, at andrewh@resonancehealth.com or +61 8 9286 5300. Invest in Resonance Health for a promising future in healthcare technology.

In the latest half-year results, Resonance Health reported a 53% revenue increase, reaching $8.0M, with a normalised EBITDA of $1.6M. The company also achieved a profit after tax of $1.5 million, a significant improvement from the previous year. They are making progress in global pharma trials, expanding their clinic network, and have a substantial pipeline of orders and bids. The new innovative technologies like the "Bridge" tool and non-invasive liver fibrosis device show promise for further growth.

Resonance Health's revenue diversification and rapid scaling across three businesses have been positive, leading to a strong CAGR of ~45% since FY23. The company's strategy focuses on expanding their share of the market by broadening therapeutic areas, offering more services to each customer, and acquiring new customers through organic or acquisitive growth.

Investors can look forward to Resonance Health's continued growth in the global clinical trial market, leveraging their deep expertise in liver and metabolic/obesity areas. The company maintains a strong financial position, disciplined cost control, and aims for responsible growth with a target EBITDA margin range of about 25%. If you have any questions about our latest announcement, feel free to ask.

Resonance Health has seen significant revenue growth and diversification since FY23, with a strong revenue growth of approximately 45% CAGR. The company has expanded its addressable global market, focusing on new imaging endpoints for metabolic and obesity, alongside a growth strategy that aims to increase share of wallet through more therapeutic areas, services, and customers. Growth opportunities include expanding into new therapeutic areas and earlier stage trials, as well as acquisitions in the US and Europe.

The company's FY26 guidance remains at a revenue of $17M and underlying Operating EBITDA of $2M, with plans to grow underlying EBITDA margins to ~12% and target margins of ~25% in the future. Resonance Health prides itself on its deep expertise in liver and related metabolic areas and serves global pharma clients with standardized trial protocols. Investors are encouraged to inquire for further details and clarification on the company's expansion plans and growth opportunities.

Resonance Health Ltd (ASX: RHT) has released an investor strategy day presentation, available for review on our website. The presentation highlights our strong revenue growth, diversified revenue streams, and dedication to scientific rigor, with a focus on providing high-quality quantitative assessments essential in managing diseases and drug development.

Our SaMD products, including FerriScan® and FerriSmart®, are regulatory cleared and internationally recognized for their accuracy in assessing liver iron concentration and fat. We also offer services in medical imaging analysis, clinical trials, and site management operations.

We invite investors to join a live webcast and Q&A session hosted by our leadership team. For further information, contact our Chief Executive Officer Andrew Harrison.

As we move forward, we are focused on expanding into new therapeutic areas, increasing our customer base, and improving operational efficiencies through technology investments. This strategic growth plan positions us for success, with a target EBITDA margin of approximately 25% and a revenue guidance of around $17 million for FY26.

If you have any questions or would like more information, please visit our website or reach out to us directly. We look forward to engaging with our stakeholders and sharing our progress.

Resonance Health

Announcements

Date	Headline
21 Oct 2026 8:22 AM	Notice of Annual General Meeting/Proxy Form
20 Oct 2026 10:01 AM	Liver Fibrosis Device - Clinical Trial Results - Webinar 2
30 Sep 2026 8:11 AM	AGM Date & Director Nomination Closing Date
24 Sep 2026 3:20 PM	Change in Substantial Holding
17 Sep 2026 9:20 AM	Global Strategic Alliance & MSA with Image Analysis Group 1
31 Aug 2026 7:29 PM	Appendix 4G & Corporate Governance Statement
28 Aug 2026 9:28 AM	FY26 Full Year Results & Investor Webinar
28 Aug 2026 9:24 AM	FY26 Full Year Results & FY27 Guidance Investor Presentation
28 Aug 2026 9:17 AM	Appendix 4E, Full Year Statutory Accounts & Annual Report
19 Aug 2026 1:35 PM	FY26 Full Year Results Webinar

Annual reports

Investor presentations